Geode Capital Management, LLC Atreca, Inc. Transaction History

Geode Capital Management, LLC

$1.12 Trillion
Q2 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$0.13 - $0.38 $4,231 - $12,368	32,548 Added 12.38%	295,471 $38,000
Q3 2023 Nov 13, 2023	BUY	$0.26 - $1.12 $3,625 - $15,616	13,943 Added 5.6%	262,923 $68,000
Q4 2022 Feb 13, 2023	SELL	$0.78 - $1.68 $14,761 - $31,794	-18,925 Reduced 7.06%	248,980 $199,000
Q3 2022 Nov 14, 2022	BUY	$1.59 - $2.74 $5,801 - $9,998	3,649 Added 1.38%	267,905 $420,000
Q2 2022 Aug 12, 2022	SELL	$1.56 - $3.25 $316,431 - $659,233	-202,841 Reduced 43.43%	264,256 $473,000
Q1 2022 May 13, 2022	SELL	$1.61 - $5.2 $175,892 - $568,100	-109,250 Reduced 18.96%	467,097 $1.48 Million
Q4 2021 Feb 11, 2022	BUY	$2.87 - $6.29 $119,397 - $261,676	41,602 Added 7.78%	576,347 $1.75 Million
Q3 2021 Nov 12, 2021	BUY	$4.91 - $9.07 $418,292 - $772,691	85,192 Added 18.95%	534,745 $3.33 Million
Q2 2021 Aug 13, 2021	SELL	$7.82 - $13.8 $44,253 - $78,094	-5,659 Reduced 1.24%	449,553 $3.83 Million
Q1 2021 May 12, 2021	BUY	$13.0 - $19.34 $819,104 - $1.22 Million	63,008 Added 16.07%	455,212 $6.98 Million
Q4 2020 Feb 12, 2021	BUY	$13.03 - $17.09 $438,303 - $574,873	33,638 Added 9.38%	392,204 $6.33 Million
Q3 2020 Nov 13, 2020	BUY	$12.67 - $23.19 $1.96 Million - $3.58 Million	154,550 Added 75.75%	358,566 $5.01 Million
Q2 2020 Aug 13, 2020	BUY	$12.52 - $23.45 $411,908 - $771,505	32,900 Added 19.23%	204,016 $4.34 Million
Q1 2020 May 14, 2020	BUY	$11.4 - $27.28 $921,963 - $2.21 Million	80,874 Added 89.62%	171,116 $2.83 Million
Q4 2019 Feb 13, 2020	BUY	$9.68 - $18.67 $436,432 - $841,755	45,086 Added 99.84%	90,242 $1.4 Million
Q3 2019 Nov 12, 2019	BUY	$10.42 - $22.04 $470,525 - $995,238	45,156 New	45,156 $552,000

Others Institutions Holding BCEL

# of Institutions

Shares Held

30.6K

Call Options Held

Put Options Held

View Full List

About Atreca, Inc.

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

More about BCEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Account